Akebia Therapeutics Stock Forecast, Price & News

-0.05 (-1.36 %)
(As of 06/14/2021 02:56 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume52,551 shs
Average Volume5.11 million shs
Market Capitalization$579.62 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Akebia Therapeutics logo

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.49 out of 5 stars

Medical Sector

601st out of 2,099 stocks

Pharmaceutical Preparations Industry

295th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

Is Akebia Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akebia Therapeutics stock.
View analyst ratings for Akebia Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Akebia Therapeutics?

Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akebia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Akebia Therapeutics

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.12. The biopharmaceutical company had revenue of $52.30 million for the quarter, compared to analysts' expectations of $43.80 million. Akebia Therapeutics had a negative net margin of 151.39% and a negative trailing twelve-month return on equity of 96.29%.
View Akebia Therapeutics' earnings history

How has Akebia Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AKBA shares have decreased by 47.6% and is now trading at $3.64.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AKBA?

7 equities research analysts have issued 12-month price targets for Akebia Therapeutics' shares. Their forecasts range from $3.00 to $18.00. On average, they expect Akebia Therapeutics' share price to reach $7.83 in the next year. This suggests a possible upside of 115.2% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 57, Pay $1.2M)
  • Mr. David A. Spellman, Sr. VP, CFO & Treasurer (Age 44, Pay $591.06k)
  • Mr. Michel Dahan, Sr. VP & COO (Age 42, Pay $655.14k)
  • Mr. Jason A. Amello, Exec. Officer (Age 53, Pay $435.66k)
  • Mr. Dell Faulkingham, Sr. VP & Chief Commercial Officer (Age 48, Pay $660.04k)
  • Dr. Steven Keith Burke, Sr. VP of R&D and Chief Medical Officer (Age 60, Pay $681.87k)
  • Ms. Violetta Cotreau, Sr. VP, Chief Accounting Officer & Principal Accounting Officer (Age 48)
  • Ms. Kristen K. Sheppard J.D., Esq., VP of Investor Relations
  • Ms. Nicole R. Hadas, Sr. VP, Chief Legal Officer & Sec. (Age 48)
  • Mr. Douglas Jermasek, VP of Marketing & Strategy

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics CEO John Butler on John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.74%), Nantahala Capital Management LLC (3.22%), Morgan Stanley (2.09%), Goldman Sachs Group Inc. (1.74%), Geode Capital Management LLC (1.63%) and Dimensional Fund Advisors LP (1.52%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, JPMorgan Chase & Co., Goldman Sachs Group Inc., Credit Suisse AG, Renaissance Technologies LLC, Squarepoint Ops LLC, AQR Capital Management LLC, and Man Group plc. Company insiders that have sold Akebia Therapeutics company stock in the last year include John P Butler, Michel Dahan, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Citigroup Inc., BlackRock Inc., Dimensional Fund Advisors LP, Rafferty Asset Management LLC, PDT Partners LLC, Mirabella Financial Services LLP, and Geode Capital Management LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $3.64.

How much money does Akebia Therapeutics make?

Akebia Therapeutics has a market capitalization of $582.82 million and generates $295.31 million in revenue each year. The biopharmaceutical company earns $-383,460,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

Akebia Therapeutics employs 379 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is

Where are Akebia Therapeutics' headquarters?

Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.